Last 12 months
Inside the activity.
0 purchase rows · 6 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2018 Filed Feb 20, 2018 18:08 UTC |
Michael Robert A.VP, Controller
|
SaleCommon stock, $0.01 par value | 592 | $120.33 | $71,235.36 |
DisclosureSEC source: 0001179110-18-002429 · edgar.xml · nonDerivative · entry 3 Michael Robert A. · CIK 0001699914 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,557 Read SEC document |
| February 20, 2018 Filed Feb 20, 2018 18:08 UTC |
Michael Robert A.VP, Controller
|
SaleCommon stock, $0.01 par value | 400 | $120.29 | $48,116.04 |
DisclosureSEC source: 0001179110-18-002429 · edgar.xml · nonDerivative · entry 2 Michael Robert A. · CIK 0001699914 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,149 Read SEC document |
| February 19, 2018 Filed Feb 20, 2018 18:08 UTC |
Michael Robert A.VP, Controller
|
Tax withholdingCommon stock, $0.01 par value | 838 | $118.60 | $99,386.80 |
DisclosureSEC source: 0001179110-18-002429 · edgar.xml · nonDerivative · entry 1 Michael Robert A. · CIK 0001699914 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,549 Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:51 UTC |
SALEKI-GERHARDT AZITASVP, Operations
|
GrantOption (right to buy) · Derivative | 23,160 | $0.00 Strike: $114.36 | $0.00 |
DisclosureSEC source: 0001179110-18-002295 · edgar.xml · derivative · entry 6 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,160 Underlying: Common Stock · 23,160 shares Expires 2028-02-14 F6 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 7,720 on February 15, 2019, 7,720 on February 15, 2020, and 7,720 on February 15, 2021. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:51 UTC |
SALEKI-GERHARDT AZITASVP, Operations
|
GrantCommon stock, $0.01 par value | 7,170 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002295 · edgar.xml · nonDerivative · entry 3 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,332 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:51 UTC |
SALEKI-GERHARDT AZITASVP, Operations
|
GrantCommon stock, $0.01 par value | 8,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002295 · edgar.xml · nonDerivative · entry 2 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,162 F2 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:51 UTC |
SALEKI-GERHARDT AZITASVP, Operations
|
GrantCommon stock, $0.01 par value | 7,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002295 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,879 F1 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:52 UTC |
Schumacher Laura JExecutive Vice President
|
GrantOption (right to buy) · Derivative | 45,840 | $0.00 Strike: $114.36 | $0.00 |
DisclosureSEC source: 0001179110-18-002296 · edgar.xml · derivative · entry 4 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,840 Underlying: Common Stock · 45,840 shares Expires 2028-02-14 F4 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 15,280 on February 15, 2019, 15,280 on February 15, 2020, and 15,280 on February 15, 2021. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:52 UTC |
Schumacher Laura JExecutive Vice President
|
GrantCommon stock, $0.01 par value | 14,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002296 · edgar.xml · nonDerivative · entry 3 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,152 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:52 UTC |
Schumacher Laura JExecutive Vice President
|
GrantCommon stock, $0.01 par value | 17,319 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002296 · edgar.xml · nonDerivative · entry 2 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,161 F2 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:52 UTC |
Schumacher Laura JExecutive Vice President
|
GrantCommon stock, $0.01 par value | 13,110 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002296 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,842 F1 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:53 UTC |
ALBAN CARLOSEVP, Commercial Operations
|
GrantOption (right to buy) · Derivative | 44,430 | $0.00 Strike: $114.36 | $0.00 |
DisclosureSEC source: 0001179110-18-002297 · edgar.xml · derivative · entry 5 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,430 Underlying: Common Stock · 44,430 shares Expires 2028-02-14 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 14,810 on February 15, 2019, 14,810 on February 15, 2020, and 14,810 on February 15, 2021. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:53 UTC |
ALBAN CARLOSEVP, Commercial Operations
|
GrantCommon stock, $0.01 par value | 14,340 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002297 · edgar.xml · nonDerivative · entry 3 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,002 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:53 UTC |
ALBAN CARLOSEVP, Commercial Operations
|
GrantCommon stock, $0.01 par value | 16,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002297 · edgar.xml · nonDerivative · entry 2 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,662 F2 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:53 UTC |
ALBAN CARLOSEVP, Commercial Operations
|
GrantCommon stock, $0.01 par value | 13,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002297 · edgar.xml · nonDerivative · entry 1 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,950 F1 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:54 UTC |
Gosebruch Henry OEVP, Chief Strategy Officer
|
GrantOption (right to buy) · Derivative | 35,440 | $0.00 Strike: $114.36 | $0.00 |
DisclosureSEC source: 0001179110-18-002298 · edgar.xml · derivative · entry 5 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,440 Underlying: Common Stock · 35,440 shares Expires 2028-02-14 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 11,814 on February 15, 2019, 11,813 on February 15, 2020, and 11,813 on February 15, 2021. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:54 UTC |
Gosebruch Henry OEVP, Chief Strategy Officer
|
GrantCommon stock, $0.01 par value | 11,730 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002298 · edgar.xml · nonDerivative · entry 3 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,218 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:54 UTC |
Gosebruch Henry OEVP, Chief Strategy Officer
|
GrantCommon stock, $0.01 par value | 13,552 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002298 · edgar.xml · nonDerivative · entry 2 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,488 F2 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:54 UTC |
Gosebruch Henry OEVP, Chief Strategy Officer
|
GrantCommon stock, $0.01 par value | 14,034 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002298 · edgar.xml · nonDerivative · entry 1 Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,936 F1 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:54 UTC |
RICHMOND TIMOTHY J.SVP, Human Resources
|
GrantOption (right to buy) · Derivative | 22,210 | $0.00 Strike: $114.36 | $0.00 |
DisclosureSEC source: 0001179110-18-002299 · edgar.xml · derivative · entry 4 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,210 Underlying: Common Stock · 22,210 shares Expires 2028-02-14 F4 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 7,404 on February 15, 2019, 7,403 on February 15, 2020, and 7,403 on February 15, 2021. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:54 UTC |
RICHMOND TIMOTHY J.SVP, Human Resources
|
GrantCommon stock, $0.01 par value | 6,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002299 · edgar.xml · nonDerivative · entry 3 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,900 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:54 UTC |
RICHMOND TIMOTHY J.SVP, Human Resources
|
GrantCommon stock, $0.01 par value | 7,902 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002299 · edgar.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,060 F2 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:54 UTC |
RICHMOND TIMOTHY J.SVP, Human Resources
|
GrantCommon stock, $0.01 par value | 7,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002299 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,158 F1 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:55 UTC |
SEVERINO MICHAELEVP, R&D and CSO
|
GrantOption (right to buy) · Derivative | 46,320 | $0.00 Strike: $114.36 | $0.00 |
DisclosureSEC source: 0001179110-18-002300 · edgar.xml · derivative · entry 4 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,320 Underlying: Common Stock · 46,320 shares Expires 2028-02-14 F4 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 15,440 on February 15, 2019, 15,440 on February 15, 2020, and 15,440 on February 15, 2021. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:55 UTC |
SEVERINO MICHAELEVP, R&D and CSO
|
GrantCommon stock, $0.01 par value | 14,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002300 · edgar.xml · nonDerivative · entry 3 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,607 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:55 UTC |
SEVERINO MICHAELEVP, R&D and CSO
|
GrantCommon stock, $0.01 par value | 17,319 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002300 · edgar.xml · nonDerivative · entry 2 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,616 F2 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:55 UTC |
SEVERINO MICHAELEVP, R&D and CSO
|
GrantCommon stock, $0.01 par value | 15,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002300 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,297 F1 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 17:56 UTC |
Michael Robert A.VP, Controller
|
GrantOption (right to buy) · Derivative | 8,030 | $0.00 Strike: $114.36 | $0.00 |
DisclosureSEC source: 0001179110-18-002301 · edgar.xml · derivative · entry 4 Michael Robert A. · CIK 0001699914 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,030 Underlying: Common Stock · 8,030 shares Expires 2028-02-14 F4 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 2,677 on February 15, 2019, 2,676 on February 15, 2020, and 2,677 on February 15, 2021. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 17:56 UTC |
Michael Robert A.VP, Controller
|
GrantCommon stock, $0.01 par value | 1,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002301 · edgar.xml · nonDerivative · entry 3 Michael Robert A. · CIK 0001699914 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,387 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 17:56 UTC |
Michael Robert A.VP, Controller
|
GrantCommon stock, $0.01 par value | 1,975 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002301 · edgar.xml · nonDerivative · entry 2 Michael Robert A. · CIK 0001699914 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,677 F2 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 17:56 UTC |
Michael Robert A.VP, Controller
|
GrantCommon stock, $0.01 par value | 1,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002301 · edgar.xml · nonDerivative · entry 1 Michael Robert A. · CIK 0001699914 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,702 F1 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 17:57 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
GrantOption (right to buy) · Derivative | 127,610 | $0.00 Strike: $114.36 | $0.00 |
DisclosureSEC source: 0001179110-18-002302 · edgar.xml · derivative · entry 7 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,610 Underlying: Common Stock · 127,610 shares Expires 2028-02-14 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 42,537 on February 15, 2019, 42,536 on February 15, 2020, and 42,537 on February 15, 2021. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 17:57 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
GrantCommon stock, $0.01 par value | 39,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002302 · edgar.xml · nonDerivative · entry 3 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,783 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 17:57 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
GrantCommon stock, $0.01 par value | 45,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002302 · edgar.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,672 F2 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 17:57 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
GrantCommon stock, $0.01 par value | 42,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002302 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,486 F1 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:59 UTC |
CHASE WILLIAM JEVP, Chief Financial Officer
|
GrantOption (right to buy) · Derivative | 45,840 | $0.00 Strike: $114.36 | $0.00 |
DisclosureSEC source: 0001179110-18-002305 · edgar.xml · derivative · entry 5 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,840 Underlying: Common Stock · 45,840 shares Expires 2028-02-14 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 15,280 on February 15, 2019, 15,280 on February 15, 2020, and 15,280 on February 15, 2021. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:59 UTC |
CHASE WILLIAM JEVP, Chief Financial Officer
|
GrantCommon stock, $0.01 par value | 14,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002305 · edgar.xml · nonDerivative · entry 3 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,798 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:59 UTC |
CHASE WILLIAM JEVP, Chief Financial Officer
|
GrantCommon stock, $0.01 par value | 17,319 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002305 · edgar.xml · nonDerivative · entry 2 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,807 F2 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:59 UTC |
CHASE WILLIAM JEVP, Chief Financial Officer
|
GrantCommon stock, $0.01 par value | 15,945 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002305 · edgar.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,488 F1 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 17:05 UTC |
TILTON GLENN FDirector
|
GrantStock Equivalent Units · Derivative | 387 | $96.71 Strike: $0.00 | $37,426.77 |
DisclosureSEC source: 0001179110-18-000327 · edgar.xml · derivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,229 Underlying: Common Stock · 387 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 22:05 UTC |
RAPP EDWARD JDirector
|
GrantStock Equivalent Units · Derivative | 338 | $96.71 Strike: $0.00 | $32,687.98 |
DisclosureSEC source: 0001179110-18-000329 · edgar.xml · derivative · entry 1 RAPP EDWARD J · CIK 0001171780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,391 Underlying: Common Stock · 338 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 17:06 UTC |
LIDDY EDWARD MDirector
|
GrantStock Equivalent Units · Derivative | 323 | $96.71 Strike: $0.00 | $31,237.33 |
DisclosureSEC source: 0001179110-18-000330 · edgar.xml · derivative · entry 1 LIDDY EDWARD M · CIK 0001188983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,664 Underlying: Common Stock · 323 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend equivalent reinvestment feature. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 22:06 UTC |
Alpern Robert JDirector
|
GrantStock Equivalent Units · Derivative | 67 | $96.71 Strike: $0.00 | $6,479.57 |
DisclosureSEC source: 0001179110-18-000331 · edgar.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,721 Underlying: Common Stock · 67 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 18, 2017 Filed Dec 19, 2017 23:09 UTC |
RICHMOND TIMOTHY J.SVP, Human Resources
|
Exercise / conversionOption (right to buy) · Derivative | 87,040 | $0.00 Strike: $35.88 | $0.00 |
DisclosureSEC source: 0001179110-17-015664 · edgar.xml · derivative · entry 3 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 87,040 shares Expires 2023-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 18, 2017 Filed Dec 19, 2017 23:09 UTC |
RICHMOND TIMOTHY J.SVP, Human Resources
|
SaleCommon stock, $0.01 par value | 87,040 | $98.45 | $8,569,053.18 |
DisclosureSEC source: 0001179110-17-015664 · edgar.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,078 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.13 to $98.86, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 18, 2017 Filed Dec 19, 2017 23:09 UTC |
RICHMOND TIMOTHY J.SVP, Human Resources
|
Exercise / conversionCommon stock, $0.01 par value | 87,040 | $35.88 | $3,122,995.20 |
DisclosureSEC source: 0001179110-17-015664 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,118 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2017 Filed Dec 15, 2017 22:13 UTC |
Schumacher Laura JExecutive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 1,143 | $0.00 Strike: $35.88 | $0.00 |
DisclosureSEC source: 0001179110-17-015438 · edgar.xml · derivative · entry 6 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,143 shares Expires 2023-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 15, 2017 Filed Dec 15, 2017 22:13 UTC |
Schumacher Laura JExecutive Vice President
|
SaleCommon stock, $0.01 par value | 1,143 | $96.86 | $110,710.98 |
DisclosureSEC source: 0001179110-17-015438 · edgar.xml · nonDerivative · entry 4 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,732 Read SEC document |
| December 15, 2017 Filed Dec 15, 2017 22:13 UTC |
Schumacher Laura JExecutive Vice President
|
Exercise / conversionCommon stock, $0.01 par value | 1,143 | $35.88 | $41,010.84 |
DisclosureSEC source: 0001179110-17-015438 · edgar.xml · nonDerivative · entry 3 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2017 Filed Dec 15, 2017 22:13 UTC |
Schumacher Laura JExecutive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 144,367 | $0.00 Strike: $35.88 | $0.00 |
DisclosureSEC source: 0001179110-17-015438 · edgar.xml · derivative · entry 5 Schumacher Laura J · CIK 0001319245 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,143 Underlying: Common stock · 144,367 shares Expires 2023-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.